New PET/MRI probe developed by IOCB Prague promises early discovery of covert diseases.

The article focuses on a novel PET/MRI contrast agent developed by IOCB Prague in collaboration with German and Czech institutions, designed to enhance disease detection through combined imaging techniques. Topics include the new contrast agent's ability to integrate MRI and PET imaging, its potential to improve diagnosis and treatment of diseases such as kidney disorders and tumors.